Skip to Main Content

Please see complete boxed warning and additional
Important Safety Information below.

Legal Notices and Disclaimers

The information provided on our website is intended for general informational and educational purposes. You should read and review these Terms of Use before accessing or using this website. By accessing or using this site, you acknowledge that you have read, understood and agreed to the Terms of Use Agreement. These Terms of Use are by and between Arbor Pharmaceuticals, LLC and you, someone who uses or accesses one of our websites. When we refer to ourselves as "we" or "Arbor Pharmaceuticals, LLC," we mean our entire company, including any company that we control (for example, a subsidiary that we own).

As-Is Presentation. Arbor Pharmaceuticals, LLC makes no warranty or representation of any kind as to the information or materials on our website. Access to and use of our website and the content thereof is at your own risk. To the maximum extent permitted by law, Arbor Pharmaceuticals, LLC disclaims any and all warranties, express or implied, including warranties of merchantability, title, and fitness for a particular purpose. Neither Arbor Pharmaceuticals, LLC nor any party involved in creating, producing, hosting or delivering this website or its contents shall be liable for any damages, including without limitation: direct, incidental, consequential, indirect, or punitive damages arising out of access to, use of or inability to use the website, or any errors or omissions in the content thereof. This limitation includes damages arising from any viruses or other harmful code that may infect your computer equipment or from malicious persons who may make unauthorized use of the website or its contents.

Linked Information. Our website may contain links or references to other websites designed, maintained, and promoted by third parties over whom Arbor Pharmaceuticals, LLC has no control. Such links are provided merely as a convenience. Similarly, this website may be accessed from third party links over whom Arbor Pharmaceuticals, LLC has no control. Arbor Pharmaceuticals, LLC makes no warranties or representations of any kind as to the accuracy, currency, or completeness of any information contained in such websites and shall have no liability for any damages or injuries of any kind arising from such content or information. Inclusion of any third party link does not imply an endorsement or recommendation by Arbor Pharmaceuticals, LLC. In the event that you follow a link to a website that is for a company or person that is not under our control, you are reminded to read the terms of use and/or legal notice at each such site, as Arbor Pharmaceuticals, LLC is not responsible for how other companies or persons treat your privacy once you leave the Arbor Pharmaceuticals, LLC website.

Medical Information. Our website may contain general medical or healthcare information that is provided for informational purposes only and should not be used in any way for medical diagnosis or treatment. The information provided on this website should be verified by a healthcare professional for accuracy, currency, completeness, and applicability to your situation before being relied upon. You should always obtain advice provided by a doctor or other qualified healthcare professional.

Non-Confidential Communication to Us. Any communication, information, materials, or items that you send to us through the Internet, electronic mail, post on our website, or otherwise, such as any questions, comments, suggestions, or the like, are and will be deemed to be non-confidential and Arbor Pharmaceuticals, LLC shall have no obligation of any kind with respect to the same. This agreement includes and incorporates by this reference, Arbor Pharmaceuticals' Privacy Policy, which you should review so as to understand Arbor Pharmaceuticals' practice and policies regarding the collection and use of information and data.

Use of Ideas You Communicate. In the event and to the extent that you have any right, title, or interest in any intellectual property contained in any communication to us, including (without limitation) moral rights, you hereby grant to Arbor Pharmaceuticals, LLC a worldwide, non-exclusive, transferable, royalty-free, fully paid-up license to use, execute, perform, display, reproduce, modify, distribute, sell, have sold, make, have made, import, export, and create derivative works that Arbor Pharmaceuticals, LLC will own, and to authorize others to do any of the same, for whatever purpose that Arbor Pharmaceuticals, LLC may choose and under all rights, title, and interest that you have, including (without limitation) all intellectual property and moral rights.

Trademarks. All product names, whether or not appearing in large print or with the trademark symbol, and all product logos, are trademarks of Arbor Pharmaceuticals, LLC, its affiliates, related companies, or its licensors or joint venture partners, unless otherwise noted. Gliadel is a registered trademark of Eisai, Inc. The use or misuse of these trademarks or any other materials, except as expressly permitted herein, and strictly within the limitations of any such permission, is expressly prohibited and may be in violation of copyright law, trademark law, the law of slander and libel, the law of privacy and publicity, and communications regulations and statutes.

Copyrights. The entire contents of this website are subject to copyright protection. Copyright ©2022 Arbor Pharmaceuticals, LLC. All rights reserved. The contents of this website may not be copied other than for non-commercial individual reference with all copyright or other proprietary notices retained, and thereafter may not be recopied, reproduced or otherwise redistributed. Except as expressly provided above, you may not otherwise copy, display, download, distribute, modify, reproduce, republish or retransmit any information, text or documents contained in this website or any portion thereof in any electronic medium or in hard copy, or create any derivative work based on such images, text or documents, without the express written consent of Arbor Pharmaceuticals, LLC. Nothing contained herein shall be construed as conferring by implication, estoppel, or otherwise any license or right under any patent or trademark of Arbor Pharmaceuticals, or any third party.

Void Where Prohibited. This website and its contents are intended to comply with the laws and regulations in the United States. While available outside the United States, the content of this website as it pertains to pharmaceutical products is intended for use only by residents of the United States. The laws and regulations of other countries may be different. Any offer for any product or service made on our website is void where prohibited by law.

User Responsibility. By using any of our websites, you agree to indemnify, defend and hold harmless Arbor Pharmaceuticals, LLC, its officers, directors, employees, agents, suppliers, and third party affiliates from and against any and all losses, expenses, damages, and costs, including reasonable attorneys' fee, resulting from any violation by you of these Terms of Use.

Governing Laws. These Terms of Use and your use of the website shall be governed by the laws of the United States of America and the State of Georgia without regard to conflict of law principles. By using this website you agree that any legal action shall be brought exclusively in a federal or state court of competent jurisdiction sitting in the U.S. state of Georgia. If any provision of these Terms of Use is held to be unlawful, void or unenforceable, then such provision shall be severable without affecting the enforceability of all remaining provisions.


See full Prescribing Information for complete boxed warning.

  • Sotalol can cause life threatening ventricular tachycardia associated with QT interval prolongation
  • Do not initiate sotalol therapy if the baseline QTc is longer than 450 ms. If the QT interval prolongs to 500 ms or greater, the dose must be reduced, the interval between doses prolonged, or the drug discontinued.
  • Patient should be hospitalized in a facility that can provide cardiac resuscitation and continuous electrocardiographic monitoring
  • Adjust the dosing interval based on creatinine clearance

Please see Important Safety Information below, as well as the full Prescribing Information.


  • Sinus bradycardia (<50 bpm during waking hours), sick sinus syndrome or second and third degree AV block unless a functioning pacemaker is present
  • Congenital or acquired long QT syndromes, baseline QT interval >450 ms
  • Cardiogenic shock, uncontrolled heart failure
  • Creatinine clearance <40 mL/min
  • Serum potassium <4 mEq/L
  • Bronchial asthma or related bronchospastic conditions
  • Known hypersensitivity to sotalol


Because of the possible life-threatening proarrhythmic effects, use of SOTYLIZE with less severe arrhythmias, even if symptomatic, is generally not recommended. Treatment of asymptomatic ventricular premature contractions should be avoided. SOTYLIZE should be reserved for patients with highly symptomatic AFIB/AFL and not for patients with paroxysmal AFIB whose AFIB/AFL is easily reversed (by Valsalva maneuver, for example).

QT Prolongation and Proarrhythmia: SOTYLIZE can cause serious ventricular arrhythmias, primarily Torsade de Pointes (TdP), a polymorphic tachycardia associated with QT interval prolongation. SOTYLIZE use in conjunction with other QT prolonging drugs has not been studied and is not recommended.

Bradycardia/Heart Block Renal Impairment: There is a direct relationship between renal function, as measured by serum creatinine or creatinine clearance, and the elimination rate of sotalol.

Sick Sinus Syndrome: SOTYLIZE is not recommended in patients with sick sinus syndrome associated with symptomatic arrhythmias because it may cause sinus bradycardia, pause or arrest. In AFIB and sinus node dysfunction, sotalol increases the risk of Torsade de Pointes, especially after cardioversion. Sotalol augments bradycardia following cardioversion. Patients with AFIB/AFL associated with the sick sinus syndrome may be treated with sotalol if they have an implanted pacemaker.

Hypotension: Monitor hemodynamics in patients with marginal cardiac compensation.

Recent Acute MI: Experience in the early phase of acute MI recovery is limited.

Abrupt Withdrawal: When discontinuing chronically administered sotalol, particularly with ischemic heart disease, carefully monitor and consider temporary use of an alternate beta-blocker if appropriate.

Electrolyte Disturbances: SOTYLIZE should not be used in patients with hypokalemia or hypomagnesemia prior to correction of imbalance, as these conditions increase the potential for Torsade de Pointes. Special attention should be given to electrolyte and acid-base balance in patients experiencing severe or prolonged diarrhea or patients receiving concomitant diuretic drugs.

Non-Allergic Bronchospasm: Patients with bronchospastic diseases should in general not receive beta-blockers. If SOTYLIZE is to be administered, use the smallest effective dose, to minimize inhibition of bronchodilation produced by endogenous or exogenous catecholamine stimulation of beta2 receptors.

Diabetes: Beta-blockade may mask some important premonitory signs of acute hypoglycemia (e.g., tachycardia) in diabetic (especially labile) patients with episodic spontaneous hypoglycemia.

Thyrotoxicosis: Beta-blockade may mask certain clinical signs (e.g., tachycardia) of hyperthyroidism. Abrupt withdrawal of SOTYLIZE may exacerbate hyperthyroid symptoms, including thyroid storm.

Anaphylaxis: While taking beta-blockers, patients with a history of severe allergic reactions may have a more severe reaction on repeated challenge, whether accidental, diagnostic, or therapeutic and may be unresponsive to the usual doses of epinephrine used to treat the reaction.


The most common adverse reactions (>10%) seen with oral sotalol (dose related) are fatigue, bradycardia, dizziness, and headache.


  • Digoxin increases the risk of proarrhythmic events
  • Calcium-blocking drugs may have additive effects on decreasing atrioventricular conduction, ventricular function, and blood pressure
  • Concomitant use of catecholamine-depleting drugs may produce hypotension, marked bradycardia, and syncope
  • Dosage of insulin or antidiabetic drugs may require adjustment
  • Dose of beta-2 receptor agonists may have to be increased
  • Sotalol may potentiate rebound hypertension after discontinuation of clonidine
  • Aluminum or magnesium-based antacids reduce sotalol exposure

You are encouraged to report side effects of prescription drugs to Arbor Pharmaceuticals, LLC Medical Information at +1-866-516-4950 or to the FDA at or call +1-800-FDA-1088.

For additional Safety information, consult the SOTYLIZE full Prescribing Information.